We are thrilled to announce that the protocol for the COMBO-UC clinical trial, led by Dr. Renata Wojnarowska, MD, PhD, Professor at the Medical University of Łódź, in collaboration with Katarzyna Płoszka, MSc, Katarzyna Błaziak, MSc, and Prof. Wojciech Fendler, MD, PhD, has been published in Frontiers in Medicine!

The article titled “Comparison of ustekinumab, infliximab and combination therapy in moderately to severely active ulcerative colitis – a study protocol of a randomized, multicenter, head-to-head COMBO-UC trial” is now available in full here.

For patients with ulcerative colitis (UC) who experience treatment failure with conventional therapy, monotherapy with biological agents has become the standard of care. However, due to the still unsatisfactory rate of clinical remission achieved with monotherapy, our COMBO-UC clinical trial proposes a novel combination therapy using two biological agents: Infliximab (IFX) and Ustekinumab (UST). This combination therapy aims to increase the rate of clinical remission and improve the quality of life for UC patients.